112 related articles for article (PubMed ID: 11342434)
1. Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.
Nagai N; De Mol M; Van Hoef B; Verstreken M; Collen D
Blood; 2001 May; 97(10):3086-92. PubMed ID: 11342434
[TBL] [Abstract][Full Text] [Related]
2. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
Nagai N; De Mol M; Lijnen HR; Carmeliet P; Collen D
Circulation; 1999 May; 99(18):2440-4. PubMed ID: 10318667
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human microplasmin: production and potential therapeutic properties.
Nagai N; Demarsin E; Van Hoef B; Wouters S; Cingolani D; Laroche Y; Collen D
J Thromb Haemost; 2003 Feb; 1(2):307-13. PubMed ID: 12871505
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Nagai N; Vanlinthout I; Collen D
Circulation; 1999 Dec 21-28; 100(25):2541-6. PubMed ID: 10604893
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers.
Pakola S; Cahillane G; Stassen JM; Lijnen HR; Verhamme P
Clin Ther; 2009 Aug; 31(8):1688-706. PubMed ID: 19808128
[TBL] [Abstract][Full Text] [Related]
6. Plasmin (Human) Administration in Acute Middle Cerebral Artery Ischemic Stroke: Phase 1/2a, Open-Label, Dose-Escalation, Safety Study.
Mitchell PJ; Yan B; Brozman M; Ribo M; Marder V; Courtney KL; Saver JL;
J Stroke Cerebrovasc Dis; 2017 Feb; 26(2):308-320. PubMed ID: 27793534
[TBL] [Abstract][Full Text] [Related]
7. Determination of plasmin-alpha 2-antiplasmin complex in plasma samples by means of a radioimmunoassay.
Wiman B; Jacobsson L; Andersson M; Mellbring G
Scand J Clin Lab Invest; 1983 Feb; 43(1):27-33. PubMed ID: 6194554
[TBL] [Abstract][Full Text] [Related]
8. Gene targeting in hemostasis. Alpha2-antiplasmin.
Lijnen HR
Front Biosci; 2001 Feb; 6():D239-47. PubMed ID: 11171550
[TBL] [Abstract][Full Text] [Related]
9. An enzyme-linked immunosorbent assay (ELISA) for the measurement of plasmin-alpha 2-antiplasmin complex in human plasma--application to the detection of in vivo activation of the fibrinolytic system.
Holvoet P; de Boer A; Verstreken M; Collen D
Thromb Haemost; 1986 Oct; 56(2):124-7. PubMed ID: 2433784
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
Shuaib A; Yang Y; Nakada MT; Li Q; Yang T
J Cereb Blood Flow Metab; 2002 Feb; 22(2):215-22. PubMed ID: 11823719
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
Zhang X; Chaudhry A; Chintala SK
Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors.
Dong W; Li N; Gao D; Zhen H; Zhang X; Li F
J Vasc Surg; 2008 Sep; 48(3):709-14. PubMed ID: 18572362
[TBL] [Abstract][Full Text] [Related]
13. In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke.
Petty MA; Neumann-Haefelin C; Kalisch J; Sarhan S; Wettstein JG; Juretschke HP
Eur J Pharmacol; 2003 Aug; 474(1):53-62. PubMed ID: 12909195
[TBL] [Abstract][Full Text] [Related]
14. The regulation of liver regeneration by the plasmin/alpha 2-antiplasmin system.
Okada K; Ueshima S; Imano M; Kataoka K; Matsuo O
J Hepatol; 2004 Jan; 40(1):110-6. PubMed ID: 14672621
[TBL] [Abstract][Full Text] [Related]
15. Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood-Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke.
Singh S; Houng AK; Reed GL
Neuroscience; 2018 Apr; 376():40-47. PubMed ID: 29294343
[TBL] [Abstract][Full Text] [Related]
16. Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
Noll G; Lämmle B; Duckert F
Thromb Haemost; 1984 Jul; 51(3):334-7. PubMed ID: 6238441
[TBL] [Abstract][Full Text] [Related]
17. Regulation of streptokinase-human plasmin complex by the plasma proteinase inhibitors alpha 2-antiplasmin and alpha 2-macroglobulin is species specific and temperature dependent.
Gonias SL; Figler NL; Braud LL
Blood; 1988 Nov; 72(5):1658-64. PubMed ID: 2460159
[TBL] [Abstract][Full Text] [Related]
18. High-dose methylprednisolone treatment in experimental focal cerebral ischemia.
Slivka AP; Murphy EJ
Exp Neurol; 2001 Jan; 167(1):166-72. PubMed ID: 11161604
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke.
Thijs VN; Peeters A; Vosko M; Aichner F; Schellinger PD; Schneider D; Neumann-Haefelin T; Röther J; Davalos A; Wahlgren N; Verhamme P
Stroke; 2009 Dec; 40(12):3789-95. PubMed ID: 19834019
[TBL] [Abstract][Full Text] [Related]
20. The suitability of various plasmin preparations for the functional assay of alpha 2-antiplasmin in plasma.
Kluft C; Traas DW; Jie AF; Hoegee-de Nobel E
Thromb Haemost; 1982 Dec; 48(3):320-4. PubMed ID: 6219471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
